Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

World Pulmonology 2020

About conference

Asia Pacific Conferences heartily welcomes you to the most prestigious 11th International Conference on Pulmonology & Respiratory Medicine during November 23-24, 2020 Tokyo, Japan.

Conference welcomes pulmonology specialists across the globe to discuss current trends in pulmonology disease screening to diagnosis, treatment and management .strategic sessions of the pulmonary covering about almost all of the pulmonology diseases such as COPD, Asthma, Allergy, Cystic fibrosis, pneumonia, tuberculosis, emphysema, Lung nodules, chronic cough, mycobacterial infection, influenza, Bronchiectasis, etc.

The Pulmonology Conference-2020 composed of well–organized scientific sessions, plenary sessions, oral presentation, poster presentation, one to one meetings, networking sessions, e-poster presentation, young Research Forums, B2B meetings, international workshops, symposiums, Industrial  sessions, Exhibitor presentation etc.

Who Should Attend?

Pulmonology Conference-2020 welcomes the multidisciplinary medical professionals, clinicians, and researchers associated with the diagnosis, treatment associated with the diagnosis, treatment and management of respiratory diseases and allied fields. This world pulmonology-2020 is the best platform that would help the pulmonologists care professionals to get the insights and latest trends to improve the patient care. All the researchers working in the field of Pulmonology, Asthma, Pneumonia, emphysema, tuberculosis, COPD, lungs diseases, Lung Cancer, complicated chest infections and other allied fields will be of interest. The Scope of this Pulmonology Conference is for the below professionals, but not limited to:

  • Pulmonologists
  • Respiratory medicine
  • Respiratory physicians
  • Respiratory disease specialists
  • Allergy and Immunology
  • General Medicine & Internal Medicine
  • Respiratory Therapy
  • Radiology & Radiotherapy
  • Physiotherapy
  • Nursing
  • Behavioral Science
  • Environmental and Occupational Health
  • Infectious Disease
  • Pediatric Pulmonary, Critical Care and Sleep
  • Cardiology

By attending the Pulmonology Conference-2020, Tokyo, Japan can get the insights of:

Recent trends & techniques of pulmonology medicine

Upgrade yourself with latest innovations to optimize the treatment process of pulmonology Diseases

Discuss the current challenges & update with future opportunities in improving respiratory care in future era

Assess the treatment gaps of various pulmonary diseases

Update yourself with new strategies of diagnosing Sleep Apnea, Asthma, Allergy, COPD and other related diseases and define the new treatment strategies

Review the efficacy of spirometer access of breathing partten and to identify various disease conditions like Asthma, COPD, pulmonary fibrosis, cystic fibrosis and to optimize the non-invasive mechanical ventilation process in case of respiratory failure.

Abstract Eligibility Criteria

AUTHOR ELIGIBILITY:

Individuals may submit up to two regular abstracts as the first author.

Individuals may submit an unlimited number of Trials in Progress abstracts.

Individuals may serve as a co-author on an unlimited number of abstracts.

ABSTRACT ELIGIBILITY

All types of Pulmonologists, Thoracic Surgeon’s, Medicinal, Health research are eligible for submission.

Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.

Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Interim analysis of a prospective randomized clinical trial will be considered if it is performed as planned in the original protocol and is statistically valid.

Abstracts of clinically-related subjects should be combined into a single abstract.

Note: Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.

Submission Requirements:

Provide your full name, academic degree(s), institution, address, and email address and recent photograph. You will receive all future correspondence from us regarding the status of your abstract.

The selected abstracts will be published in Conference Proceedings.

Sessions/ Tracks

Track 1: Chronic Obstructive Pulmonary Disease 

Chronic obstructive Pulmonary Disease is a constant incendiary lung illness that causes discouraged wind stream from the lungs. Side effects incorporate breathing trouble, hack, bodily fluid creation and wheezing. It's brought about by long haul introduction to disturbing gases or particulate issue, frequently from tobacco smoke. Individuals with COPD are at expanded danger of creating coronary illness, lung malignancy and an assortment of different conditions. The top reason for COPD is tobacco smoking. Long haul introduction to synthetic aggravations can likewise prompt COPD. It's a sickness that generally sets aside a long effort to create

Diagnosis usually involves imaging tests, blood tests, and lung function tests. There's no solution for COPD, yet treatment can help ease manifestations, bring down the opportunity of intricacies, and for the most part improve personal satisfaction. Meds, supplemental oxygen treatment, and medical procedure are a few types of treatment. Early indications incorporate into COPD are incidental brevity of breath, particularly after exercise, mellow however repetitive hack and expecting to make a sound as if to speak regularly, particularly before anything else.

Track 2: Pulmonary Rehabilitation

Pulmonary rehabilitation also known as respiratory rehabilitation is an important part of the management and health maintenance of people with chronic respiratory disease who remain symptomatic or continue to have decreased function despite standard medical treatment. It is defined by the American Thoracic Society and the European Respiratory Society as an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. In general, pulmonary rehabilitation refers to a series of services that are administered to patients of respiratory disease and their families, typically to attempt to improve the quality of life for the patient.

Pulmonary rehabilitation may be carried out in a variety of settings, depending on the patient's needs, and may or may not include pharmacologic intervention. Pulmonary rehabilitation is generally specific to the individual patient, with the objective of meeting the needs of the patient. It is a broad program and may benefit patients with lung diseases such as chronic obstructive pulmonary disease (COPD), sarcoidosis, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis, among others. Although the process is focused on the rehabilitation of the patient him/herself, the family is also involved. The process typically does not begin until a medical exam of the patient has been performed by a licensed physician.

Track 03Pulmonary Hypertension

Pulmonary hypertension is a type of high blood pressure that affects the arteries in lungs and the right side of heart. In one form of pulmonary hypertension, tiny arteries in lungs, called pulmonary arterioles, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through lungs, and raises pressure within lungs' arteries. As the pressure builds, the heart's lower right chamber (right ventricle) must work harder to pump blood through the lungs, eventually causing heart muscle to weaken and fail

Each form of Pulmonary hypertension is different, so it is important for newly-diagnosed patients to find a Pulmonary hypertension specialist who can accurately find what is causing their Pulmonary hypertension and develop a treatment plan that is right for that specific type of Pulmonary hypertension as soon as possible. Every person with pulmonary hypertension is different, and new research is being conducted every day with the potential to improve the outlook for people living with this disease. Once in the care of a pulmonary hypertension treating health care team and on appropriate therapy, people with pulmonary hypertension can live many years.

Track 4: Cardio Pulmonary Border 

Cardiopulmonary disease is the medical term used to describe a range of serious disorders that affect the heart and lungs. The two primary tobacco-related cardiopulmonary diseases are Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disorder (COPD). Exposure to tobacco smoke has long been recognized as a prominent risk factor for CVD. Similarly minimizing exposure to tobacco smoke is the only effective way to prevent COPD. However, the mechanisms by which tobacco toxicants increase the risk of CVD and lead to the onset of COPD are still unclear. Despite reductions in smoking over the past decade, CVD and COPD remain the first and second leading causes of death among smokers. It is important to remember also that for every person who dies because of smoking; at least 30 people live with a serious smoking-related illness.

The emergence of e-cigarettes and other new tobacco products that deliver nicotine aerosolized in various solvents raises new critical questions regarding the potential risk for cardiopulmonary disease among users. The use of these new tobacco products has soared over the last few years, particularly among adolescents, and is expected to overtake the conventional cigarette market within the next decade. These new products deliver nicotine and chemical flavorings aerosolized in a base of propylene glycol and/or glycerin via inhalation

Track 5: Allergy and Asthma

Allergic asthma is asthma caused by an allergic reaction. It’s also known as allergy-induced asthma. People with allergic asthma usually start feeling symptoms after inhaling an allergen such as pollen. The Asthma and Allergy Foundation of America reports that more than half of people with asthma have allergic asthma. Allergic asthma is treatable in most cases. An allergen is a typically harmless substance such as dust mites, pet dander, pollen or mold. If you are allergic to a substance, this allergen triggers a response starting in the immune system. Through a complex reaction, these allergens then cause the passages in the airways of the lungs to become inflamed and swollen. This results in coughing, wheezing and other asthma symptoms

The same allergens that give some people sneezing fits and watery eyes can cause an asthma attack in others. Allergic asthma is the most common type of asthma. About 90% of kids with childhood asthma have allergies, compared with about 50% of adults with asthma. The symptoms that go along with allergic asthma show up after you breathe things called allergens like pollen, dust mites, or mold. If you have asthma it usually gets worse after you exercise in cold air or after breathing smoke, dust, or fumes. Sometimes even a strong smell can set it off.

Track 6: Airway and Therapeutic Devices 

Positive airway pressure (PAP) therapy is a generic term applied to all sleep apnea treatments that use a stream of compressed air to support the airway during sleep. With PAP therapy, you wear a mask during sleep. A portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing. For optimal improvement, it's important to use your PAP machine every time you sleep including naps. Overall PAP therapy is a safe and effective treatment; however there are a few counter-indications.

A major determining factor of upper airway patency during sleep is the activity of the genioglossus muscle. Activation of this muscle via stimulation of the hypoglossal nerve is a creative new approach for treatment of obstructive sleep apnea (OSA). Hypoglossal nerve stimulation therapy is commonly referred to as Inspire, a reference to the name of the company Inspire Medical Systems that developed the treatment, which was approved by the Food and Drug Administration in 2014

Track 7: Lung cancer

Lung cancer is a condition that causes cells to divide in the lungs uncontrollably. This causes the growth of tumors that reduce a person's ability to breathe. In lung cancer, this pattern of cell overgrowth occurs in the lungs, which are vital organs for breathing and gas exchange. Cigarette smoking is the principal risk factor for development of lung cancer, Passive exposure to tobacco smoke (passive smoking) also can cause lung cancer in non-smokers. The two types of lung cancer, which grow and spread differently, are small-cell lung cancers (SCLC) and non-small-cell lung cancers (NSCLC). Medical professionals also refer to them as small-cell lung carcinoma and non q-small-cell lung carcinoma.

The stage of lung cancer refers to the extent to which the cancer has spread in the body. Treatment of lung cancer can involve a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy as well as newer experimental methods. The general prognosis of lung cancer is poor because doctors tend not to find the disease until it is at an advanced stage. Five-year survival is around 54% for early stage lung cancer patients that have a tumor localized to the lungs, but only around 4% in those with advanced, inoperable lung cancer. Smoking cessation is the most important measure that can prevent the development of lung cancer

Track 08: Interstistial Lung Disease

Lung cancer is a condition that causes cells to divide in the lungs uncontrollably. This causes the growth of tumors that reduce a person's ability to breathe. In lung cancer, this pattern of cell overgrowth occurs in the lungs, which are vital organs for breathing and gas exchange. Cigarette smoking is the principal risk factor for development of lung cancer, Passive exposure to tobacco smoke (passive smoking) also can cause lung cancer in non-smokers. The two types of lung cancer, which grow and spread differently, are small-cell lung cancers (SCLC) and non-small-cell lung cancers (NSCLC). Medical professionals also refer to them as small-cell lung carcinoma and non q-small-cell lung carcinoma.

The stage of lung cancer refers to the extent to which the cancer has spread in the body. Treatment of lung cancer can involve a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy as well as newer experimental methods. The general prognosis of lung cancer is poor because doctors tend not to find the disease until it is at an advanced stage. Five-year survival is around 54% for early stage lung cancer patients that have a tumor localized to the lungs, but only around 4% in those with advanced, inoperable lung cancer. Smoking cessation is the most important measure that can prevent the development of lung cancer.

Track 9: Pediatric Pulmonology & Critical care

Respiratory implies the field of drug identifying with lung and respiratory issue. Working with general pediatrics, aspiratory pediatricians treat an extensive variety of pneumonic issue. Respiratory implies the field of solution identifying with lung and respiratory issue. Working with general pediatrics, aspiratory pediatricians treat an extensive variety of pneumonic issue. It incorporates Asthma, Sleep Disorder, Chronic Cough, Exercise initiated Asthma, Congenital Lung Problem and Pediatric Pneumonia.

A great part of the focal point of aspiratory recovery, look into and pneumonic solution goes toward the most youthful individuals from society-the babies. It's inherent however treatable. With a sound aspiratory stenosis finding the heart valve can be supplanted or repaired and kids can develop to lead ordinary solid lives. Rest apnea influences untimely infants. A circumstance called apnea of rashness exists when the tyke doesn't breath for 20 seconds or more. It's a pneumonic illness that can be treated with ventilation machines and medicines.

Track 10: Lung Transplantation

Lung cancer is a condition that causes cells to divide in the lungs uncontrollably. This causes the growth of tumors that reduce a person's ability to breathe. In lung cancer, this pattern of cell overgrowth occurs in the lungs, which are vital organs for breathing and gas exchange. Cigarette smoking is the principal risk factor for development of lung cancer, Passive exposure to tobacco smoke (passive smoking) also can cause lung cancer in non-smokers. The two types of lung cancer, which grow and spread differently, are small-cell lung cancers (SCLC) and non-small-cell lung cancers (NSCLC). Medical professionals also refer to them as small-cell lung carcinoma and non q-small-cell lung carcinoma.

The stage of lung cancer refers to the extent to which the cancer has spread in the body. Treatment of lung cancer can involve a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy as well as newer experimental methods. The general prognosis of lung cancer is poor because doctors tend not to find the disease until it is at an advanced stage. Five-year survival is around 54% for early stage lung cancer patients that have a tumor localized to the lungs, but only around 4% in those with advanced, inoperable lung cancer. Smoking cessation is the most important measure that can prevent the development of lung cancer

Market Analysis

Market Analysis

The global respiratory drugs market size will grow by USD 17.67 billion during 2018-2022. This industry research report provides a detailed analysis of the market based on type (asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, cystic fibrosis, idiopathic pulmonary fibrosis, and other respiratory disorders.

The increase in incidences and prevalence of respiratory disorders is driving global respiratory drugs market. Several types of respiratory diseases such as COPD, asthma, and acute respiratory infections are on the rise causing major mortality and disease burden on patients. Moreover, respiratory diseases account for more than millions of deaths in developing countries with a high number of cases reported for children. This created the need for management and treatment of respiratory diseases, which in turn, drives the respiratory drugs market.

The respiratory care devices market is segmented into three major end user segments—hospitals, home care settings, and ambulatory care centers. In 2019, hospitals accounted for the largest market share of the market, mainly because of their financial capabilities, which allow them to purchase high-priced instruments and the availability of trained professionals to operate these instruments have ensured the high share of hospitals in this market. Home care settings are expected to witness the highest growth during the forecast period, mainly due to the development of compact and lightweight respiratory care devices that are easier to carry and operate

The global mechanical ventilator market size was valued at USD 3.7 billion in 2016 and is expected grow at a CAGR of 6.5% during the forecast period. The evolution of patient-friendly, cost-effective and portable devices further encourage their usage.

Past Conference

 

To Collaborate Scientific Professionals around the World

Conference Date November 23-24, 2020

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Supported By

Pulmonary & Respiratory Medicine Journal of Clinical Respiratory Diseases & Care: Open Access Journal of Pulmonary Medicine

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by